Brief: Insilico Medicine Announces Oral Presentation At Esmo 2026 For Phase 1 Clinical Study Of Ism6331 In Mesothelioma And Advanced Solid Tumors
27/07/2026 13:05
BRIEF-Insilico Medicine Announces Oral Presentation At Esmo 2026 For Phase 1 Clinical Study Of Ism6331 In Mesothelioma And Advanced Solid Tumors July 27 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK:
INSILICO MEDICINE ANNOUNCES ORAL PRESENTATION AT ESMO 2026 FOR PHASE 1 CLINICAL STUDY OF ISM6331 IN MESOTHELIOMA AND ADVANCED SOLID TUMORS
Source text: ID:nPn8vdsTya
Further company coverage: 3696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7